NCT06644443
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
TEAEs
Timeframe: From date of initial treatment to the 30 days after treatment
Secondary (1)
Disease-related clinical responses
Arms and interventions
Experimental:Treatment groupExperimental
patients treated with BCMA-GPRC5D CAR-T cells
Biologicals: BCMA-GPRC5D CAR-T cells
Sites
1 site in 1 country
- Shenzhen University General HospitalShenzhen, Guangdong, China